Home  |  Punch  |  Vanguard   |  The Nation  |  Thisday  |  Daily Sun  |  Guardian  |  The Authority  |  Daily Times  |  Daily Trust  |  Daily Independent  |  The Herald  |   Tribune  |  Leadership  |  National Mirror  |  BusinessDay  |  New Telegraph  |  Peoples Daily  |  Blueprint  |  Nigerian Pilot  |  Sahara Reporters  |  Premium Times  |  The Cable  |  PM News  |  Nairametrics  |  APO Africa Newsroom  |  Tori  |  Linda Ikeji  |  Bella Naija  |  Pulse  |  Goal  |  Ftbpro  |  Techcabal  |  Techpoint  |  Techcrunch  |  BBC  |  CNN  |  World  |  Sports  |  Technology  |  Entertainment  |  Business  |  Politics  |  Features  |  Columns  |  All Headlines  |  More Channels...

Its too soon to give out Ebola drugs

Published by The Nation on Thu, 14 Aug 2014

Why would the United States decline to provide a serum that can cure Ebola to poor and desperate victims in several African nations where close to 1,000 people have died of the virus' Because it doesnt have such a serum.What the U.S. does have are a number of possible treatments for Ebola that are in the experimental stages. Most were developed with the help of federal financing after 9/11; drug companies previously had little financial incentive to develop drugs for an illness that affected relatively few people, all of them in developing countries. But after the 2001 attacks, the government became interested in staving off possible bioterrorism.Some of the treatments look very promising after early trials on animals. But it is not yet known whether any of them will cure or prevent the illness in humans, or even whether they are safe for humans to take. Nor is it known which among them would prove the most helpful.As it happens, the experimental treatment that two American aid workers were given after being stricken with Ebola in Liberia was ZMapp, a cocktail of three monoclonal antibodies. Both patients, who are being cared for at Emory University Hospital, are improving, an outcome that has governments in the affected African countries as well as three highly regarded Ebola experts clamoring to have the serum released to the hundreds of people who are infected.That would be premature. Its a big leap to assume that the two Americans were saved by the serum. About 45% of those afflicted in the West Africa epidemic have survived. The Americans may have been lucky, or they may have benefited from their access to far better medical care than most Africans get, or perhaps they can thank their own robust immune systems, a result of growing up with adequate food, clean water and other benefits of the developed world.The decision to provide the two aid workers with the serum, though well intentioned, of course, has raised serious ethical and political questions. To many Africans, it looks as though rules were bent on behalf of a couple of white Americans, while the hundreds of infected people in Africa are receiving no special treatment. Given the high mortality rate of the disease, they demand to know, shouldnt the serum be available to all' Isnt an experimental treatment better than nothing'There is no easy answer to this emotionally wrenching question. The chief argument for holding off on ZMapps releasethat it isnt known whether the drug will help or even whether it might harm the very people it is intended to save, and that safety trials must be completed before it is widely distributedsounds cold-hearted, as though it is about following bureaucratic drug approval protocols rather than helping the dying. Yet the argument is a powerful one.Perhaps the answer would be different if this epidemic carried the 90% mortality rate that Ebola has sometimes inflicted in the past. If the prognosis were a virtually terminal one, it would make sense to conclude that even a drug that might harm people is better than near-certain death. But thats not the case with this epidemic.This is a decision that has to be made carefully and rationally, though without delay. Not because the world doesnt care about the lives of the victims but because it also cares about the lives of the thousands who might be infected in the future.There are other promising Ebola treatments that are in Phase I safety trials; ZMapp hasnt reached that stage yet. It might make more sense, public health experts say, to make available the medications that are at least part of the way through safety testing.One possible treatment, not yet in safety trials, is intended to prevent the disease in people who have been exposed to the virus; a version of it was given several years ago to a German researcher who had accidentally pricked herself with an Ebola-infected syringe. She did not become illthough again, its not known for certain whether her good fortune had anything to do with the experimental treatment. Still, if it is effective, many more lives might be saved by providing medication to prevent the disease rather than to treat those who are infected. That would give health workers a chance to get ahead of the epidemic instead of reacting to each new case.Some medications may be more effective than others, but without random, controlled clinical trials, scientists may never learn which are which. Without trials, the United States or the World Health Organization might commit too early to the widespread use of a less useful treatment, or one that is far more expensive and thus would not reach as many people.At the same time, it is our moral responsibility to look for ways to speed reasonably safe medications to those who need them. The U.S. Food and Drug Administration should approve expedited safety trials that take a month or so, instead of the six months that full Phase I trials require. It would take at least that long anyway for pharmaceutical companies to ramp up production from tiny batches intended for trials to thousands of doses to cover affected populations. Then the FDA should allow its existing animal rule to apply to Ebola drugs. The rule allows efficacy trials on two different kinds of animals to substitute for human trialsas long as safety tests have been done on healthy human volunteerswhen randomized, controlled efficacy tests on humans arent practical.Even with pharmaceutical treatment, it would take a massive public health and education effort to bring the West Africa epidemic to a close any time soon, and at that point there will be time for fuller testing. But if anything, this epidemic teaches us that when it comes to developing lifesaving pharmaceuticals, we dont always have as much time as we think. Los Angeles Times]]>
Click here to read full news..

The Nation Headlines Today

FRSC kicks off Operation Show Your Drivers Licence

Ganging up against North wont give you president in 2023

Northern groups knock IPOB over sit-at-home order

Why boosting local capacities will reduce reliance on overseas tests, by firm

No going back on Anambra guber election INEC

At the mercy of middlemen

Olu of Warri disrobes Emami as Ologbotsere

Nigeria missing as UK recognises COVID vaccine certificates from over 50 countries

Killings in southeast

Click to view all The Nation headlines today

Politics Headlines Today

10,000 vulnerable Kogi citizens to access free quality healthcare - Blueprint

15-year-old details harrowing days as captive to ruthless gang - CNN

2020 recruitment exercise of 10,000 constables into Nigeria Police Force continues - Tribune

2022: Community asks Fayemi to pick successor from Ekiti South - Punch

2022: Ebira community makes case for Ekiti South - The Sun

2022: Ebira community urges Fayemi to pick successor from Ekiti South - Punch

2023 Elections: Be guided by diplomatic practices, Buhari urges Foreign Envoys - Vanguard

2023 elections: Buhari urged diplomats to stay away from partisanship - The Sun

2023 Polls: Buhari Tasks Foreign Envoys On Neutrality - Leadership

Click to view all Politics headlines today

Entertainment Headlines Today

#BBNaijaShineYaEye Finalists are The Sassy Six on the Cover of ThisDay Styles Latest Edition - Bellanaija

"Get your facts right before you accuse someone" Paul O, owner of company that managed Maria Chike, warns Cubana Chief Priest - Linda Ikeji

"How Are People Supposed to Survive'" - TBoss Cries Out Over Increase in Price of Cooking Gas - Tori

"How are people supposed to survive'"- TBoss laments increase in price of cooking gas - Linda Ikeji

"Nobody should blame Maria" Actress Charity Nnaji blames Cubana Chief Priest's "brother-in-law" for creating the environment that allowed the sidechic disrespect the wife - Linda Ikeji

"Now I know the meaning of for better and for worse"- Janemena writes as she shares video from the night her husband proposed to her - Linda Ikeji

"She stole my sister's husband" Cubana Chief Priest calls out BBNaija's Maria as he warns women to hide their husband's from her - Linda Ikeji

10 lessons I learnt in 10 years as lingerie entrepreneur, by Brief Essentials CEO - New Telegraph

10-year-old Favour Hopes to Positively Change Childrens Attitudes on Life with Her Book The King Must Not Die - Bellanaija

Click to view all Entertainment headlines today

Sports Headlines Today

10 Realistic Predictions for 2022 NBA Trade Deadline - Bleacher Report

2020/2021 CAF Champions League: Rivers United fall to Sudan's Al Hilal - Vanguard

2021 MLB Free Agents: Latest Rumors, Predictions Before World Series - Bleacher Report

2022 National Sports Festival: 'How Delta State Will Host The Best Games In History' 'Okowa - Complete Sports

3 Takeaways from 49ers' Week 7 Loss - Bleacher Report

3 Takeaways from Bears' Week 7 Loss - Bleacher Report

3 Takeaways from Chiefs' Week 7 Loss - Bleacher Report

3 Takeaways from Eagles' Week 7 Loss - Bleacher Report

3 Takeaways from Giants' Week 7 Win - Bleacher Report

Click to view all Sports headlines today

News Archive
Nigerian Dailies: Punch  |  Vanguard   |  The Nation  |  Thisday  |  Daily Sun  |  Guardian  |  The Authority  |  Daily Times  |  Daily Trust  |  Daily Independent  |   The Herald  |  Tribune  |  Leadership  |  National Mirror  |  BusinessDay  |  New Telegraph  |  Peoples Daily  |  Blueprint  |  Nigerian Pilot  |  Sahara Reporters  |  Premium Times  |  The Cable  |  Osun Defender  |  PM News  |  APO Africa Newsroom

Categories Today: World  |  Sports  |  Technology  |  Entertainment  |  Business  |  Politics  |  Columns  |  All Headlines Today

Entertainment (Local): Linda Ikeji  |  Bella Naija  |  Tori  |  Pulse  |  The NET  |  DailyPost  |  Information Nigeria  |  Gistlover  |  Lailas Blog  |  Miss Petite  |  Olufamous  |  Stella Dimoko Korkus Blog  |  Ynaija  |  All Entertainment News Today

Entertainment (World): TMZ  |  Daily Mail  |  Huffington Post

Sports: Goal  |  African Football  |  Bleacher Report  |  FTBpro  |  Kickoff  |  All Sports Headlines Today

Business & Finance: Nairametrics  |  Nigerian Tenders  |  Business Insider  |  Forbes  |  Entrepreneur  |  The Economist  |  BusinessTech  |  Financial Watch  |  BusinessDay  |  All Business News Headlines Today

Technology (Local): Techpoint  |  TechMoran  |  TechCity  |  Innovation Village  |  IT News Africa  |  Technology Times  |  Technext  |  Techcabal  |  All Technology News Headlines Today

Technology (World): Techcrunch  |  Techmeme  |  Slashdot  |  Wired  |  Hackers News  |  Engadget  |  Pocket Lint  |  The Verge

International Networks:   |  CNN  |  BBC  |  Al Jazeera  |  Associated Press  |  Yahoo

Forum:   |  Nairaland  |  Naij

Other Links: Home   |  Nigerian Jobs   |  Desktop Version

External Links